ClinicalTrials.gg
Sign In
Not yet recruitingNCT07892469Updated Oct 23, 2026

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Intravenous Doses of NH302 Injection in Healthy Participants

A Phase 1 interventional study of NH302 injection and Placebo in Healthy Volunteers, sponsored by The Third Xiangya Hospital of Central South University. Not yet recruiting. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by The Third Xiangya Hospital of Central South University · Phase 1, Interventional, and Other

Updated Oct 23, 2026Newly registeredGo to Updates ↓
Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a first-in-human study of NH302 injection in healthy participants. The study will test single intravenous doses of NH302 to evaluate its safety and tolerability, how the body processes NH302, and its effects on selected pharmacodynamic markers. Approximately 62 healthy adults will participate. Participants will receive one dose of NH302 or placebo. The study includes screening, baseline, treatment, and follow-up.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) Phase 1 study of NH302 injection in healthy participants. Six dose levels are planned: 0.15, 0.45, 1, 2, 3.5, and 5 μg/kg. Each dose group plans to enroll 10 participants, randomized 8:2 to NH302 or placebo. A pilot cohort of 2 participants will receive NH302 0.15 μg/kg before formal dose escalation. NH302 is administered as a single intravenous infusion over 15 minutes ± 10 seconds on Day 1. The study evaluates safety, tolerability, pharmacokinetics, metabolism and excretion, QT/QTc effects, and exploratory pharmacodynamic markers including prolactin, antidiuretic hormone, and pain tolerance time.

02

Conditions studied

  • Healthy Volunteers

Browse trials for

Keywords

  • NH302
  • kappa opioid receptor agonist
  • acute pain
  • safety
  • tolerability
  • pharmacokinetics
  • single ascending dose
  • healthy volunteers
03

In context

Acute Pain

908 studies on the registry are indexed under Acute Pain; 154 are open to participants now.

This study's planned enrollment of 62 is below the median of 87 across 759 interventional studies indexed under Acute Pain.

Browse Acute Pain studies →

Lead sponsor

The Third Xiangya Hospital of Central South University is the lead sponsor of 98 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female participants aged 18 to 45 years, inclusive, at screening.
  • Body mass index (BMI) of 19 to 26 kg/m², inclusive, and body weight ≥45 kg.
  • Participant fully understands the purpose, content, procedures, and potential risks of the study, voluntarily agrees to participate, and signs the informed consent form.
  • Able to communicate well with the investigator and willing and able to comply with the lifestyle restrictions and study procedures specified in the protocol.

Exclusion criteria

Exclusion Criteria:

  • History or presence of any disease or dysfunction that, in the investigator's judgment, may affect the clinical trial, including but not limited to chronic or severe diseases of the central nervous system, cardiovascular system, respiratory system, digestive system, urinary system, endocrine system, blood and lymphatic system, or psychiatric disorders.
  • Abnormal QT/QTc at baseline, including QTcF ≥450 ms; other risk factors for torsades de pointes (e.g., heart failure, hypokalemia, hypomagnesemia, family history of long QT syndrome); or potential bundle branch block.
  • Clinically significant abnormalities on physical examination, vital signs, hematology, blood chemistry, urinalysis, coagulation, thyroid function tests, chest X-ray, abdominal ultrasound, or 12-lead ECG.
  • History of severe drug allergy (known or suspected allergy to NH302 injection or its excipients), severe specific allergic disease/history (e.g., asthma, urticaria, eczematous dermatitis), or severe allergic constitution (two or more food or drug allergies).
  • Medical conditions that may induce or worsen somnolence or dizziness, including active dizziness, motion sickness, history of orthostatic hypotension, history of syncope, history of vertigo (including Meniere's disease), moderate-to-severe sleep apnea syndrome, narcolepsy, or other conditions manifested by somnolence or dizziness.
  • Need to drive, work at heights, operate precision machinery, or perform other activities requiring high alertness within 24 hours after discharge from the study and unable to suspend these activities.
  • History of drug abuse, drug dependence, or substance abuse within 1 year before screening, or positive urine drug screen.
  • Use of any hepatic enzyme inhibitor or inducer within 1 month before screening (e.g., inducers: phenobarbital, rifampicin, carbamazepine, phenytoin, dexamethasone; inhibitors: fluvoxamine, S-mephenytoin, propofol, isoniazid, phenothiazines).
  • Received an inactivated vaccine within 1 month before screening; received an inactivated or live attenuated vaccine within 3 months before screening; or plans to receive an inactivated or live attenuated vaccine during the study.
  • Blood loss or donation of more than 400 mL within 3 months before screening (excluding menstrual bleeding in women); transfusion or receipt of blood products exceeding 400 mL within 3 months before the trial; or plans to donate blood during the study or within 1 month after study completion.
  • History of surgery within 3 months before screening, incomplete recovery from surgery, or planned surgery during the study.
  • Use of any prescription drug, over-the-counter drug, herbal medicine, or dietary supplement (including vitamins and health products) within 2 weeks before dosing or within 5 half-lives of the drug, whichever is longer.
  • History of alcohol abuse within 6 months before screening (i.e., more than 14 standard units per week; 1 unit = 360 mL beer, 45 mL of 40% spirits, or 150 mL wine), positive alcohol breath test (result >0), or inability to abstain from alcohol during the study.
  • Positive smoking test; smoking ≥5 cigarettes per day within 6 months before screening; or inability to stop using any tobacco product (including nicotine gum or transdermal nicotine patches) during the study.
  • Intake of caffeine-containing food or beverages (e.g., coffee, strong tea, chocolate, caffeine-containing carbonated drinks, cola) within 48 hours before screening.
  • Intake of any glucose-rich beverage or food within 48 hours before screening.
  • Special dietary requirements, inability to comply with a standardized diet, or dysphagia; or anorexia, dieting, or significant abnormal diet (e.g., dieting, low sodium) started within 4 weeks before screening.
  • Positive or non-negative results for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), HIV antibody (HIV-Ab), or Treponema pallidum (TP) antibody.
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >1.5 × upper limit of normal (ULN); or creatinine (Cr), blood urea nitrogen (BUN), or urea >ULN.
  • Difficulty with blood sampling, intolerance to venipuncture, or history of hemophobia or needle phobia.
  • Pregnant or breastfeeding women at screening; or participants who refuse to use effective contraception (e.g., abstinence, intrauterine device) during the study and within 3 months after study completion, or who plan to donate sperm or oocytes.
  • Participation in any clinical trial within 3 months before dosing or still in the follow-up period of another trial.
  • Poor expected compliance or any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    NH302 0.15 μg/kg

    Single intravenous dose of NH302 0.15 μg/kg, diluted in 0.9% sodium chloride, total volume 20 mL, infused over 15 minutes ± 10 seconds on Day 1.

    Drug: NH302 injection

  • Placebo comparator
    Placebo for 0.15 μg/kg group

    Single intravenous dose of matching placebo, total volume 20 mL, infused over 15 minutes ± 10 seconds on Day 1.

    Drug: Placebo

  • Experimental
    NH302 0.45 μg/kg

    Single intravenous dose of NH302 0.45 μg/kg, diluted in 0.9% sodium chloride, total volume 20 mL, infused over 15 minutes ± 10 seconds on Day 1.

    Drug: NH302 injection

  • Placebo comparator
    Placebo for 0.45 μg/kg group

    Single intravenous dose of matching placebo, total volume 20 mL, infused over 15 minutes ± 10 seconds on Day 1.

    Drug: Placebo

  • Experimental
    NH302 1 μg/kg

    Single intravenous dose of NH302 1 μg/kg, diluted in 0.9% sodium chloride, total volume 20 mL, infused over 15 minutes ± 10 seconds on Day 1.

    Drug: NH302 injection

  • Placebo comparator
    Placebo for 1 μg/kg group

    Single intravenous dose of matching placebo, total volume 20 mL, infused over 15 minutes ± 10 seconds on Day 1.

    Drug: Placebo

  • Experimental
    NH302 2 μg/kg

    Single intravenous dose of NH302 2 μg/kg, diluted in 0.9% sodium chloride, total volume 20 mL, infused over 15 minutes ± 10 seconds on Day 1.

    Drug: NH302 injection

  • Placebo comparator
    Placebo for 2 μg/kg group

    Single intravenous dose of matching placebo, total volume 20 mL, infused over 15 minutes ± 10 seconds on Day 1.

    Drug: Placebo

  • Experimental
    NH302 3.5 μg/kg

    Single intravenous dose of NH302 3.5 μg/kg, diluted in 0.9% sodium chloride, total volume 20 mL, infused over 15 minutes ± 10 seconds on Day 1.

    Drug: NH302 injection

  • Placebo comparator
    Placebo for 3.5 μg/kg group

    Single intravenous dose of matching placebo, total volume 20 mL, infused over 15 minutes ± 10 seconds on Day 1.

    Drug: Placebo

  • Experimental
    NH302 5 μg/kg

    Single intravenous dose of NH302 5 μg/kg, diluted in 0.9% sodium chloride, total volume 20 mL, infused over 15 minutes ± 10 seconds on Day 1.

    Drug: NH302 injection

  • Placebo comparator
    Placebo for 5 μg/kg group

    Single intravenous dose of matching placebo, total volume 20 mL, infused over 15 minutes ± 10 seconds on Day 1.

    Drug: Placebo

Interventions

  • DrugNH302 injection

    NH302 is a selective peripheral kappa opioid receptor agonist. It is supplied as a sterile injection (1 mL: 0.1 mg). For each dose group, NH302 is diluted with 0.9% sodium chloride injection to a total volume of 20 mL and administered as a single intravenous infusion over 15 minutes ± 10 seconds on Day 1. Dose levels: 0.15, 0.45, 1, 2, 3.5, and 5 μg/kg. The dose is calculated based on body weight on Day 1.

  • DrugPlacebo

    Matching placebo supplied by the sponsor (1 mL: 0 mg). It has the same appearance as NH302 injection and is prepared and administered in the same manner to maintain blinding: total volume 20 mL, single intravenous infusion over 15 minutes ± 10 seconds on Day 1.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    Number and percentage of participants with AEs

    Time frame: From informed consent form signature through end of study (Day 7 ± 1 day after dosing, or longer if follow-up is required).

  2. Incidence of serious adverse events (SAEs)

    Number and percentage of participants with SAEs

    Time frame: From informed consent form signature through end of study (Day 7 ± 1 day after dosing, or longer if follow-up is required).

  3. Blood pressure

    Systolic and diastolic blood pressure will be measured in mmHg after at least 5 minutes of rest in the supine position. Blood pressure will be measured at the scheduled time points listed in the Time Frame; values at each scheduled time point will be reported separately. Assessments performed at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Screening (Day -14 to Day -2), Baseline (Day -1); Day 1 predose and at 5 minutes, 10 minutes, 30 minutes, 1 hour, 4 hours, and 6 hours postdose; Day 2 (24 hours postdose); Day 3 (48 hours postdose); Day 4 (discharge)

  4. Pulse rate

    Pulse rate will be measured in beats per minute after at least 5 minutes of rest in the supine position. Pulse rate will be measured at the scheduled time points listed in the Time Frame; values at each scheduled time point will be reported separately. Assessments performed at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Screening (Day -14 to Day -2), Baseline (Day -1); Day 1 predose and at 5 minutes, 10 minutes, 30 minutes, 1 hour, 4 hours, and 6 hours postdose; Day 2 (24 hours postdose); Day 3 (48 hours postdose); Day 4 (discharge)

  5. Respiratory rate

    Respiratory rate will be measured in breaths per minute after at least 5 minutes of rest in the supine position. Values at each scheduled time point listed in the Time Frame will be reported separately. Assessments performed at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Screening (Day -14 to Day -2), Baseline (Day -1); Day 1 predose and at 5 minutes, 10 minutes, 30 minutes, 1 hour, 4 hours, and 6 hours postdose; Day 2 (24 hours postdose); Day 3 (48 hours postdose); Day 4 (discharge)

  6. Body temperature

    Body temperature will be measured in degrees Celsius (°C) at the scheduled time points listed in the Time Frame; values at each scheduled time point will be reported separately. Assessments performed at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Screening (Day -14 to Day -2), Baseline (Day -1), Day 1 (predose and at 5 minutes, 10 minutes, 30 minutes, 1 hour, 4 hours, and 6 hours postdose), Day 2 (24 hours postdose), Day 3 (48 hours postdose), and Day 4 (discharge)

  7. Number of Participants With Clinically Significant Physical Examination Abnormalities

    Physical examinations will be performed by organ system, including general appearance, lymph nodes, head and neck, chest, abdomen, and mental status. Any finding will be assessed by the investigator as clinically significant (CS) or not clinically significant (NCS). This outcome measure reports the number and percentage of participants with at least one CS physical examination abnormality at each scheduled time point; multiple organ-system abnormalities in the same participant will be aggregated and counted once for this outcome measure. If the screening examination is performed within 7 days before Baseline, the Baseline examination may not be repeated, per protocol. Assessments performed at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Screening (Day -14 to Day -2), Baseline (Day -1) and Day 4 (discharge)

  8. Number of Participants With Clinically Significant Clinical Laboratory Abnormalities

    Clinical laboratory tests include hematology, blood chemistry, urinalysis, coagulation, and thyroid function tests, as specified in the protocol. Each laboratory abnormality will be assessed by the investigator as clinically significant (CS) or not clinically significant (NCS). This outcome measure reports the number and percentage of participants with at least one CS laboratory abnormality at each scheduled time point; multiple CS abnormalities in the same participant will be aggregated and counted once for this outcome measure. If screening laboratory tests are performed within 7 days before Baseline, the Baseline tests may not be repeated, per protocol. Assessments performed at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Screening (Day -14 to Day -2), Baseline (Day -1) and Day 4 (discharge)

  9. Number of Participants With Clinically Significant 12-Lead ECG Abnormalities

    Twelve-lead ECGs will be recorded after at least 5 minutes of rest in the supine position. ECG parameters include heart rate, PR interval, QRS duration, QT interval, QTcF, and RR interval. Each ECG finding will be assessed by the investigator as clinically significant (CS) or not clinically significant (NCS). This outcome measure reports the number and percentage of participants with at least one CS 12-lead ECG abnormality at each scheduled time point; multiple ECG abnormalities in the same participant will be aggregated and counted once for this outcome measure. If the screening ECG is performed within 7 days before Baseline, the Baseline ECG may not be repeated, per protocol. Assessments performed at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Screening (Day -14 to Day -2), Baseline (Day -1), Day 1 (predose and at 30 minutes, 1 hour, 4 hours, and 6 hours postdose), Day 2 (24 hours postdose), Day 3 (48 hours postdose), and Day 4 (discharge)

  10. Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score

    MOAA/S score ranges from 0 to 5; lower scores indicate deeper sedation.

    Time frame: Day 1 predose, immediately after injection, and at 5 minutes, 30 minutes, 1 hour, 3 hours, 6 hours, 10 hours, 24 hours after injection, and early withdrawal (within 24 hours after dosing).

  11. Visual analogue scale (VAS) craving score

    VAS craving score ranges from 0 to 10; 0 = no craving, 10 = extreme craving.

    Time frame: Day 1 immediately after injection, and at 5 minutes, 30 minutes, 1 hour, 3 hours, 6 hours, 10 hours, 24 hours after injection, and early withdrawal (within 24 hours after dosing).

  12. Number of Participants With Clinically Significant Thyroid Function Test Abnormalities

    Thyroid function tests include total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine (FT3), free thyroxine (FT4), and thyroid stimulating hormone (TSH). Each test result will be assessed by the investigator as clinically significant (CS) or not clinically significant (NCS). This outcome measure reports the number and percentage of participants with at least one CS thyroid function test abnormality at each scheduled time point; multiple CS abnormalities in the same participant will be aggregated and counted once for this outcome measure. Assessments performed at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Screening (Day -14 to Day -2), Baseline (Day -1), and Day 4 (discharge)

Secondary outcomes

  1. Plasma Cmax of NH302 and metabolites, if applicable

    Plasma concentrations of NH302 and metabolites (if applicable) will be measured by HPLC-MS/MS. Cmax will be derived from the concentration-time data and reported in ng/mL for NH302 and for each metabolite separately. Blood samples for PK will be collected predose and from 15 seconds to 48 hours postdose. PK samples collected at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Day 1 (predose) through 48 hours postdose

  2. Plasma Tmax of NH302 and metabolites, if applicable

    Plasma concentrations of NH302 and metabolites (if applicable) will be measured by HPLC-MS/MS. Tmax will be derived from the concentration-time data and reported in hours for NH302 and for each metabolite separately. Blood samples for PK will be collected predose and from 15 seconds to 48 hours postdose. PK samples collected at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Day 1 (predose) through 48 hours postdose

  3. Plasma AUC0-t of NH302 and metabolites, if applicable

    Plasma concentrations of NH302 and metabolites (if applicable) will be measured by HPLC-MS/MS. AUC0-t will be calculated from time zero to the last quantifiable time point using the linear trapezoidal rule and reported in h·ng/mL for NH302 and for each metabolite separately. Blood samples for PK will be collected predose and from 15 seconds to 48 hours postdose. PK samples collected at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Day 1 (predose) through 48 hours postdose

  4. Plasma AUC0-inf of NH302 and metabolites, if applicable

    Plasma concentrations of NH302 and metabolites (if applicable) will be measured by HPLC-MS/MS. AUC0-inf will be calculated as AUC0-t plus Clast/λz, where Clast is the last quantifiable plasma concentration and λz is the terminal elimination rate constant, and will be reported in h·ng/mL for NH302 and for each metabolite separately. The percentage of AUC0-inf obtained by extrapolation will also be reported. Blood samples for PK will be collected predose and from 15 seconds to 48 hours postdose. PK samples collected at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Day 1 (predose) through 48 hours postdose

  5. Plasma AUC_%Extrap of NH302 and metabolites, if applicable

    Plasma concentrations of NH302 and metabolites (if applicable) will be measured by HPLC-MS/MS. The percentage of AUC0-inf obtained by extrapolation (AUC\_%Extrap) will be calculated as \[(AUC0-inf - AUC0-t) / AUC0-inf\] × 100% and reported as a percentage for NH302 and for each metabolite separately. Blood samples for PK will be collected predose and from 15 seconds to 48 hours postdose. PK samples collected at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Day 1 (predose) through 48 hours postdose

  6. Plasma Clearance (CL) of NH302 and Metabolites, if Applicable

    Plasma concentrations of NH302 and metabolites (if applicable) will be measured by HPLC-MS/MS. CL will be calculated as the administered dose divided by AUC0-inf and reported in mL/h/kg for NH302. For metabolites, CL will be reported only if the administered dose and a reliable AUC0-inf are available; otherwise, metabolite concentration and AUC will be reported without CL. Blood samples for PK will be collected predose and from 15 seconds to 48 hours postdose. PK samples collected at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Day 1 (predose) through 48 hours postdose

  7. Plasma Apparent Volume of Distribution (Vz) of NH302 and Metabolites, if Applicable

    Plasma concentrations of NH302 and metabolites (if applicable) will be measured by HPLC-MS/MS. Vz will be calculated as CL/λz, where CL is clearance and λz is the terminal elimination rate constant, and reported in mL/kg for NH302. For metabolites, Vz will be reported only if the administered dose and a reliable AUC0-inf and λz are available; otherwise, metabolite concentration and AUC will be reported without Vz. Blood samples for PK will be collected predose and from 15 seconds to 48 hours postdose. PK samples collected at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Day 1 (predose) through 48 hours postdose

  8. Plasma Terminal Elimination Rate Constant (λz) of NH302 and Metabolites, if Applicable

    Plasma concentrations of NH302 and metabolites (if applicable) will be measured by HPLC-MS/MS. λz will be estimated by linear regression of the log-transformed plasma concentration versus time during the terminal elimination phase, using the negative slope, and will be reported in h-¹ for NH302 and for each metabolite separately. For metabolites, λz will be reported only if a reliable terminal elimination phase can be identified; otherwise, metabolite concentration and AUC will be reported without λz. Blood samples for PK will be collected predose and from 15 seconds to 48 hours postdose. PK samples collected at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Day 1 (predose) through 48 hours postdose

  9. Plasma Terminal Elimination Half-life (t1/2) of NH302 and Metabolites, if Applicable

    Plasma concentrations of NH302 and metabolites (if applicable) will be measured by HPLC-MS/MS. t1/2 will be calculated as ln(2)/λz, where λz is the terminal elimination rate constant estimated from the terminal phase of the concentration-time curve, and will be reported in hours for NH302 and for each metabolite separately. For metabolites, t1/2 will be reported only if a reliable terminal elimination phase can be identified; otherwise, metabolite concentration and AUC will be reported without t1/2. Blood samples for PK will be collected predose and from 15 seconds to 48 hours postdose. PK samples collected at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Day 1 (predose) through 48 hours postdose

  10. Plasma Mean Residence Time from Time Zero to Infinity (MRT0-inf) of NH302 and Metabolites, if Applicable

    Plasma concentrations of NH302 and metabolites (if applicable) will be measured by HPLC-MS/MS. MRT0-inf will be calculated as AUMC0-inf/AUC0-inf, where AUMC0-inf is the area under the first moment curve from time zero to infinity and AUC0-inf is the area under the concentration-time curve from time zero to infinity, and will be reported in hours for NH302 and for each metabolite separately. For metabolites, MRT0-inf will be reported only if a reliable AUC0-inf and AUMC0-inf can be calculated; otherwise, metabolite concentration and AUC will be reported without MRT. Blood samples for PK will be collected predose and from 15 seconds to 48 hours postdose. PK samples collected at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Day 1 (predose) through 48 hours postdose

  11. Urinary Excretion Amount of NH302 and Metabolites in Each Collection Interval (Ae_t1-t2), if Applicable

    Urine samples will be collected only in the 1 μg/kg dose cohort. Concentrations of NH302 and metabolites (if applicable) in urine will be measured by HPLC-MS/MS. Ae\_t1-t2 will be calculated for each urine collection interval as the urine concentration multiplied by the urine volume collected during that interval, and will be reported in μg for NH302 and for each metabolite separately. Urine collection intervals are predose (morning dose day, tentative) and 0-2, 2-4, 4-8, 8-12, 12-24, and 24-48 hours postdose; if no urine is produced during an interval, that interval will not be collected and will be recorded. Urine samples collected at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Day 1 (predose) and 0-2, 2-4, 4-8, 8-12, 12-24, and 24-48 hours postdose

  12. Cumulative Urinary Excretion Amount of NH302 and Metabolites (Ae_0-t), if Applicable

    Urine samples will be collected only in the 1 μg/kg dose cohort. Concentrations of NH302 and metabolites (if applicable) in urine will be measured by HPLC-MS/MS. Ae\_0-t will be calculated as the cumulative urinary excretion amount from time zero to the last collection interval (48 hours postdose) by summing the excretion amounts across all scheduled urine collection intervals, and will be reported in μg for NH302 and for each metabolite separately. If no urine is produced during an interval, that interval will not be collected and will be recorded. Urine samples collected at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Day 1 (predose) through 48 hours postdose

  13. Cumulative Urinary Excretion Fraction (fe) of NH302 and Metabolites, if Applicable

    Urine samples will be collected only in the 1 μg/kg dose cohort. Concentrations of NH302 and metabolites (if applicable) in urine will be measured by HPLC-MS/MS. Cumulative urinary excretion fraction (fe) will be calculated as the cumulative urinary excretion amount from time zero to 48 hours postdose divided by the administered dose, multiplied by 100%, and will be reported as a percentage for NH302 and for each metabolite separately. Urine collection intervals are predose (morning of dosing day, tentative) and 0-2, 2-4, 4-8, 8-12, 12-24, and 24-48 hours postdose; if no urine is produced during an interval, that interval will not be collected and will be recorded. Urine samples collected at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Day 1 (predose) through 48 hours postdose

  14. Renal Clearance (CLr) of NH302 and Metabolites, if Applicable

    Urine samples will be collected only in the 1 μg/kg dose cohort. Concentrations of NH302 and metabolites (if applicable) in urine and plasma will be measured by HPLC-MS/MS. CLr will be calculated as the cumulative urinary excretion amount from time zero to 48 hours postdose divided by the corresponding plasma AUC over the same interval, and will be reported in mL/min for NH302 and for each metabolite separately. For metabolites, CLr will be reported only if reliable urinary excretion and plasma AUC data are available; otherwise, metabolite concentration and AUC will be reported without CLr. If no urine is produced during a collection interval, that interval will not be collected and will be recorded. Urine and plasma samples collected at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Day 1 (predose) through 48 hours postdose

  15. Cumulative Fecal Excretion Amount (Ae_0-t) of NH302 and Metabolites, if Applicable

    Fecal samples will be collected only in the 1 μg/kg dose cohort. Concentrations of NH302 and metabolites (if applicable) in feces will be measured by HPLC-MS/MS. Ae\_0-t will be calculated as the cumulative fecal excretion amount from time zero to 48 hours postdose by summing the excretion amount for each fecal sample collected during the interval, and will be reported in μg for NH302 and for each metabolite separately. If no bowel movement occurs within 48 hours postdose, fecal collection will continue until collection is complete, and the actual collection period will be recorded. Fecal samples collected at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Day 1 (predose) through 48 hours postdose; extended until fecal collection is complete if no bowel movement occurs within 48 hours postdose

  16. Cumulative Fecal Excretion Fraction (fe) of NH302 and Metabolites, if Applicable

    Fecal samples will be collected only in the 1 μg/kg dose cohort. Concentrations of NH302 and metabolites (if applicable) in feces will be measured by HPLC-MS/MS. Cumulative fecal excretion fraction (fe) will be calculated as the cumulative fecal excretion amount from time zero to 48 hours postdose divided by the administered dose, multiplied by 100%, and will be reported as a percentage for NH302 and for each metabolite separately. If no bowel movement occurs within 48 hours postdose, fecal collection will continue until collection is complete, and the actual collection period will be recorded. Fecal samples collected at early withdrawal, if applicable, will be reported separately as unscheduled data and are not included in the protocol-scheduled Time Frame.

    Time frame: Day 1 (predose) through 48 hours postdose; extended until fecal collection is complete if no bowel movement occurs within 48 hours postdose

  17. Change from baseline in QTcF interval

    QTcF interval change from baseline based on Holter ECG.

    Time frame: Day 1 predose (-60, -45, -30 minutes), immediately after injection (+5 minutes), and at 10 minutes, 30 minutes, 1 hour, 4 hours, 6 hours, 10 hours, 24 hours after injection (Day 2).

  18. Concentration-QTc (C-QTc) analysis

    Exposure-response analysis using matched PK concentrations and ECG data to evaluate potential QT/QTc prolongation risk.

    Time frame: Day 1 predose through 24 hours after injection (Day 2); matched PK and ECG time points.

Other outcomes

  1. Prolactin level

    Change from baseline in blood prolactin level.

    Time frame: Day 1 predose, immediately after injection, and at 30 minutes, 1 hour, 3 hours, 6 hours, 24 hours after injection; early withdrawal (within 24 hours after dosing).

  2. Antidiuretic hormone (ADH) level

    Change from baseline in blood ADH level.

    Time frame: Day 1 predose, immediately after injection, and at 30 minutes, 1 hour, 3 hours, 6 hours, 24 hours after injection; early withdrawal (within 24 hours after dosing).

  3. Pain tolerance time (PTT)

    Time to withdraw hand from ice water bath; maximum 120 seconds to avoid cold injury.

    Time frame: Day 1 predose, and at 30 minutes, 1 hour, 3 hours, 6 hours, 10 hours, 24 hours after injection; early withdrawal (within 24 hours after dosing). Post-dose time windows are ±30 minutes.

07

Study locations

No study locations are listed for this record.

08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07892469
Lead sponsor
The Third Xiangya Hospital of Central South University
Collaborators
Jiangsu Nhwa Pharmaceutical Co., Ltd.
Responsible party
Guoping Yang (Professor of Clinical Pharmacology, The Third Xiangya Hospital of Central South University) — Principal investigator
First posted
Oct 23, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Acute Pain →

Other studies from this sponsor

The Third Xiangya Hospital of Central South University

Start the discussion